Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 3:37 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 10,624 matching trials from the live ClinicalTrials.gov search.

Filters: Pittsburgh, Pennsylvania Clear all

Conditions: Cancer
Interventions: Pemetrexed, Bevacizumab; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Melanoma
Interventions: Intismeran autogene, Pembrolizumab, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,089 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 34
States / cities: Springdale, Arkansas • Los Angeles, California • San Francisco, California + 27 more

Conditions: Endometrial Cancer
Interventions: Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 62
States / cities: Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 56 more

Conditions: Prostate Cancer
Interventions: Docetaxel, Prednisone; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: Male only
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 33
States / cities: Birmingham, Alabama • Tucson, Arizona • North Little Rock, Arkansas + 30 more

Conditions: Critical Limb Ischemia
Interventions: Open surgical revascularization, Endovascular revascularization; Procedure · Device
Lead sponsor: Carelon Research; Other
Eligibility: 18 Years and older
Enrollment: 1,843 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 144
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 102 more

Conditions: Labor Pain
Interventions: Ultrasound, Palpation; Device · Other
Lead sponsor: Thomas J. Vernon; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab, Phase II ARRY-614 + nivolumab+ipilimumab (melanoma), Phase II ARRY-614 + nivolumab+ipilimumab (RCC); Drug
Lead sponsor: Dan Zandberg; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Vaginitis, Bacterial Vaginosis, Yeast Vaginitis, Trichomonas Vaginitis
Interventions: Xpert® Xpress MVP test, Usual Care; Diagnostic Test
Lead sponsor: Sharon L Hillier; Other
Eligibility: 14 Years and older · Female only
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Triple Negative Breast Neoplasms
Interventions: ladiratuzumab vedotin, Pembrolizumab; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 26
States / cities: Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more

Conditions: Type2 Diabetes, Dyslipidemia
Interventions: K-877, Placebo; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 10,544 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 242
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Mobile, Alabama + 192 more

Conditions: Stroke, Spinal Cord Injuries and Disorders, Hemiparesis After Stroke
Interventions: Spinal Cord Stimulator (Medtronic Inceptiv™ System), Physical Therapy; Device · Other
Lead sponsor: Marco Capogrosso; Other
Eligibility: 22 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Gaucher Disease, Type 1
Interventions: Eliglustat tartrate, Imiglucerase; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 17
States / cities: Beverly Hills, California • San Francisco, California • Aurora, Colorado + 13 more

Conditions: Phenylketonuria (PKU)
Interventions: Pegvaliase; Drug
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 17
States / cities: Gainesville, Florida • Tampa, Florida • Chicago, Illinois + 14 more

Conditions: Venous Stasis Ulcer
Interventions: Compression wrapping, Flexitouch compression pump; Procedure
Lead sponsor: West Penn Allegheny Health System; Other
Eligibility: 18 Years to 90 Years
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 2
States / cities: Cleveland, Ohio • Pittsburgh, Pennsylvania

Conditions: Urinary Incontinence
Interventions: retropubic mid-urethral sling (TVT), transobturator mid-urethral sling (TVT-O and the Monarc); Procedure
Lead sponsor: Carelon Research; Other
Eligibility: 21 Years and older · Female only
Enrollment: 597 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2013
U.S. locations: 11
States / cities: Birmingham, Alabama • San Diego, California • Maywood, Illinois + 7 more

Conditions: Asthma
Interventions: Dulera; Drug
Lead sponsor: Asthma Management Systems; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Paroxysmal Atrial Fibrillation
Interventions: Ablation Procedure; Device
Lead sponsor: Heart Rhythm Clinical and Research Solutions, LLC; Other
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 21
States / cities: Birmingham, Alabama • Mobile, Alabama • Ventura, California + 17 more

Conditions: Neisseria Gonorrhoeae Infection, Chlamydia Trachomatis Infection, Sexually Transmitted Infections
Interventions: Nucleic acid amplification test 1 for NG and CT, Nucleic acid amplification test 2 for NG and CT, Nucleic acid amplification test 3 for NG and CT; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 2,767 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: Hollywood, California • Los Angeles, California • Denver, Colorado + 5 more

Conditions: Endometrial Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Leiomyoma
Interventions: Not listed
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years and older · Female only
Enrollment: 7,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Detroit, Michigan • Durham, North Carolina + 3 more

Conditions: Colorectal Cancer
Interventions: ALIMTA, Oxaliplatin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 22
States / cities: Huntsville, Alabama • Pittsfield, Massachusetts • Kalamazoo, Michigan + 19 more

Conditions: Alzheimer Disease
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 75 Years and older
Enrollment: 650 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 39
States / cities: Birmingham, Alabama • Sun City, Arizona • Irvine, California + 30 more

Conditions: Abortion in First Trimester
Interventions: Dextromethorphan Hydrobromide, Avicel PH101 (Microcrystalline Cellulose NF) for Compounding, Oxycodone; Drug
Lead sponsor: Study Investigator-Sponsor; Other
Eligibility: 18 Years and older · Female only
Enrollment: 156 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Adenocarcinoma
Interventions: Positron Emission Tomography, Lymphadenectomy, Radiation Therapy, Abiraterone Acetate, Prednisone, Computed Tomography, Abiraterone, PSMA PET Scan; Procedure · Radiation · Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2037
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Seattle, Washington

Conditions: Narcolepsy Without Cataplexy, Narcolepsy With Cataplexy
Interventions: Pitolisant; Drug
Lead sponsor: Harmony Biosciences Management, Inc.; Industry
Eligibility: 18 Years and older
U.S. locations: 71
States / cities: Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 60 more

Search by objective public record fields.

Study of Pemetrexed and Bevacizumab in Patients With Head and Neck Cancer

A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

Best Endovascular vs. Best Surgical Therapy in Patients With Critical Limb Ischemia

Use of Ultrasound Guidance to Assist With Labor Epidural Placement in Patients With a BMI ≥40

Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab

Point of Care Diagnosis of Vaginal Infections

Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer

Pemafibrate to Reduce Cardiovascular OutcoMes by Reducing Triglycerides IN patiENts With diabeTes (PROMINENT)

Spinal Cord Stimulation Combined With Physical Therapy in Post-Stroke Upper-Limb Motor Hemiparesis

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

Safety and Efficacy of Self Administered Injections of Pegvaliase (>40mg/Day Dose) in Adults With PKU

Flexitouch Compression System for Venous Stasis Ulcer

TOMUS-Trial Of Mid-Urethral Slings

Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence

The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation.

Performance of Nucleic Acid Amplification Tests for the Detection of NG and CT

Tissue Bank of Biological Specimens From Patients With Gynecologic Disease

A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.

Healthy Aging and Memory Study

Dextromethorphan as a Novel Non-opioid Adjunctive Agent for Pain Control in Medication Abortion

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study

Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy